Nanotechnology for Targeted Drug Delivery to Treat Osteoporosis

Curr Drug Targets. 2023;24(1):2-12. doi: 10.2174/1389450123666221004124040.

Abstract

Bone diseases such as rheumatoid arthritis, Paget's disease, and osteoporosis cause mortality and mobility limits. Nanomedicine and nano delivery systems have been utilised to deliver active drug moiety to the precisely targeted site in a controlled manner, and it serves as a means of diagnostic tools. The utilisation of nanomedicine is expanding vigorously for assured targeting and efficient drug delivery. Nanotechnology offers various advantages, such as site-specific targeting, precise drug release kinetics, and improved bone mineral density. Recent medications available for osteoporosis are not viable due to the adverse effects associated with them and low patient compliance. There is an urgent need to develop biocompatible and appropriate drug delivery nanocarriers such as nanoparticles, liposomes, hydrogels, dendrimers, micelles, mesoporous particles, etc. These carriers enhance drug delivery and therapeutic effectiveness in bone tissues. The use of nanotechnology is also associated with toxicity. This article presents the review of various reports on nanocarrier systems and biologics for the treatment of osteoporosis. It aims to provide researchers with a clue for inventing a new drug delivery system with site-specific targeting for the treatment of osteoporosis.

Keywords: Nanotechnology; biologics; bone diseases; nanomaterials; nanostructured carriers; nanotoxicity; osteoporosis.

MeSH terms

  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Liposomes
  • Nanomedicine
  • Nanoparticles* / therapeutic use
  • Nanotechnology
  • Osteoporosis* / drug therapy

Substances

  • Liposomes
  • Drug Carriers